Increased plasma DYRK1A with aging may protect against neurodegenerative diseases

Autor: Jean M. Delabar, Julien Lagarde, Marta Fructuoso, Ammara Mohammad, Michel Bottlaender, Eric Doran, Ira Lott, Isabelle Rivals, Frederic A. Schmitt, Elizabeth Head, Marie Sarazin, Marie-Claude Potier

Publikováno v: Translational Psychiatry, Vol 13, Iss 1, Pp 1-8 (2023)

Abstract Early markers are needed for more effective prevention of Alzheimer’s disease. We previously showed that individuals with Alzheimer’s disease have decreased plasma DYRK1A levels compared to controls. We assessed DYRK1A in the plasma of c

Externí odkaz: https://doaj.org/article/5d6a3bb197104b249fcbd404915e0cfc

Rodent models in Down syndrome research: impact and future opportunities

Autor: Yann Herault, Jean M. Delabar, Elizabeth M. C. Fisher, Victor L. J. Tybulewicz, Eugene Yu, Veronique Brault

Publikováno v: Disease Models & Mechanisms, Vol 10, Iss 10, Pp 1165-1186 (2017)

Down syndrome is caused by trisomy of chromosome 21. To date, a multiplicity of mouse models with Down-syndrome-related features has been developed to understand this complex human chromosomal disorder. These mouse models have been important for dete

Externí odkaz: https://doaj.org/article/790ab10207ce407489ca7bf4394b9b77

DYRK1A: A master regulatory protein controlling brain growth

Autor: Fayçal Guedj, Patricia Lopes Pereira, Sonia Najas, Maria-Jose Barallobre, Caroline Chabert, Benoit Souchet, Catherine Sebrie, Catherine Verney, Yann Herault, Mariona Arbones, Jean M. Delabar

Publikováno v: Neurobiology of Disease, Vol 46, Iss 1, Pp 190-203 (2012)

Copy number variation in a small region of chromosome 21 containing DYRK1A produces morphological and cognitive alterations in human. In mouse models, haploinsufficiency results in microcephaly, and a human DYRK1A gain-of-function model (three allele

Externí odkaz: https://doaj.org/article/db3d5b2c8d124690bf6c0cdc300b6366

DYRK1A and cognition: A lifelong relationship

Autor: Maria L. Arbonés, Aurore Thomazeau, Akiko Nakano-Kobayashi, Masatoshi Hagiwara, Jean M. Delabar

Publikováno v: Pharmacology and Therapeutics
Pharmacology and Therapeutics, Elsevier, 2019, 194, pp.199-221. ⟨10.1016/j.pharmthera.2018.09.010⟩

The dosage of the serine threonine kinase DYRK1A is critical in the central nervous system (CNS) during development and aging. This review analyzes the functions of this kinase by considering its interacting partners and pathways. The role of DYRK1A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::368aacffc3cabb1344735c323497e59b
https://doi.org/10.1016/j.pharmthera.2018.09.010

Combined assessment of DYRK1A, BDNF and homocysteine levels as diagnostic marker for Alzheimer's disease

Autor: Anne Badel, Maria L. Arbonés, A. C. Camproux, Jean-Louis Paul, P. Lamourette, Foudil Lamari, Stéphanie Simon, Marie-Claude Potier, Nathalie Janel, Cécile Feraudet-Tarisse, Jean M. Delabar, Bruno Dubois, Julien Lagarde, Panagiotis Alexopoulos, Marie Sarazin

Publikováno v: Translational Psychiatry
Translational Psychiatry, Nature Pub. Group, 2017, 7, pp.e1154. ⟨10.1038/tp.2017.123⟩
Translational Psychiatry, 2017, 7, pp.e1154. ⟨10.1038/tp.2017.123⟩
Translational Psychiatry, 2017, 7, pp.e1154. 〈10.1038/tp.2017.123〉
Digital.CSIC. Repositorio Institucional del CSIC
instname

Early identification of Alzheimer’s disease (AD) risk factors would aid development of interventions to delay the onset of dementia, but current biomarkers are invasive and/or costly to assess. Validated plasma biomarkers would circumvent these cha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29f79094776d60309b8ce82a86a591d1
https://hal.sorbonne-universite.fr/hal-01556869